New patent for the Janssen Biotech drug BALVERSA – DrugPatentWatch
Annual Drug Patent Expiration for BALVERSA
Balversa is a drug marketed by Janssen Biotech and included in one NDA. It is available from a single supplier. There are five patents protecting this drug.
This drug has one hundred and fifty patent family members in forty-three countries.
The generic ingredient in BALVERSA is erdafitinib. One registered supplier for this compound. Additional details are available on the erdafitinib profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
Make Better Decisions with DrugPatentWatch
» Start Your Free Trial Today «
Copyright © DrugPatentWatch. Originally published in New patent for the Janssen Biotech drug BALVERSA
